Indivior Pharmaceuticals, Inc.
$32.42
▼
-0.59%
2026-04-21 07:31:00
www.indivior.com
NMS: INDV
Explore Indivior Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.95 B
Current Price
$32.42
52W High / Low
$38 / $8.69
Stock P/E
31.62
Book Value
$-0.78
Dividend Yield
—
ROCE
92.33%
ROE
-96.33%
Face Value
—
EPS
$1.64
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
827
Beta
1.21
Debt / Equity
-3.55
Current Ratio
0.71
Quick Ratio
0.54
Forward P/E
8.87
Price / Sales
3.08
Enterprise Value
$3.98 B
EV / EBITDA
10.01
EV / Revenue
3.21
Rating
None
Target Price
$46.86
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Caring Brands, Inc. | $1.25 | — | — | — | -157.44% | -2.17% | $6 / $0.06 | $0.14 |
| 2. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
| 3. | Supernus Pharmaceuticals, Inc. | $51.25 | — | $2.92 B | — | -3.31% | -3.68% | $59.68 / $29.16 | $18.48 |
| 4. | Zoetis Inc. | $118.25 | 19.63 | $49.71 B | 1.64% | 27.18% | 65.99% | $172.23 / $113.29 | $7.84 |
| 5. | Kamada Ltd. | $8.32 | 23.76 | $479.95 M | 3% | 7.92% | 7.64% | $9.35 / $6.35 | $4.66 |
| 6. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 7. | Sunshine Biopharma, Inc. | $1.02 | — | $5.05 M | — | -23.97% | -25.68% | $2.43 / $0.95 | $5.31 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 358 M | 314 M | 302 M | 266 M | 299 M | — |
| Operating Profit | 83 M | 44 M | 71 M | 68 M | 292 M | — |
| Net Profit | 102 M | 42 M | 18 M | 47 M | 59 M | — |
| EPS in Rs | 0.84 | 0.34 | 0.15 | 0.39 | 0.48 | 0.03 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.24 B | 1.19 B | 1.09 B | 901 M |
| Operating Profit | 265 M | 234 M | 247 M | 215 M |
| Net Profit | 210 M | 7 M | -126 M | -44 M |
| EPS in Rs | 1.72 | 0.06 | -1.03 | -0.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.2 B | 1.32 B | 1.76 B | 1.77 B |
| Total Liabilities | 1.3 B | 1.65 B | 1.95 B | 1.72 B |
| Equity | -99 M | -337 M | -192 M | 51 M |
| Current Assets | 652 M | 827 M | 1.27 B | 1.26 B |
| Current Liabilities | 914 M | 924 M | 1.29 B | 1.02 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -27 M | 36 M | -300 M | -4 M |
| Investing CF | -66 M | 69 M | -95 M | -222 M |
| Financing CF | -30 M | -102 M | -64 M | -101 M |
| Free CF | -94 M | 5 M | -353 M | -9 M |
| Capex | -67 M | -31 M | -53 M | -5 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 8.69% | 21.31% | — | — |
| Earnings Growth % | 105.56% | -186.36% | — | — |
| Profit Margin % | 0.59% | -11.53% | -4.88% | — |
| Operating Margin % | 19.7% | 22.6% | 23.86% | — |
| Gross Margin % | 80.56% | 84.08% | 83.24% | — |
| EBITDA Margin % | 7.49% | -8.69% | -5.11% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.